POSTPARTUM DEPRESSION DRUG MARKET ANALYSIS

Postpartum depression (PPD), also known as postnatal depression, is a type of mood disorder that results post pregnancy. Signs of depression include, insomnia, fatigue and sadness, loss of appetite, mood swings, anxiety, and anger. Hormonal changes such as elevated prolactin levels, depleted oxytocin and thyroid hormone levels can be a cause of PPD in females.

Postpartum Depression Drug Market– Drivers

Increasing research activities for treatment of PPD is expected to propel growth of the postpartum depression drug market during the forecast period. For instance, Sage Therapeutics is undergoing phase 3 clinical study for the drug —Brexanolone, which might be useful in the treatment of PPD. The study started in May 2018 and is estimated to be completed in September 2020.

Furthermore, Marinus Pharmaceuticals, is undergoing clinical phase 2 study for the drug Ganaxolone in the treatment of PPD and other mood associated disorders. The clinical study started in June 2017 and is expected to be completed in June 2019.

Postpartum Depression Drug Market– Restraint

Antidepressant drugs refusals by the U.S. Food and Drug Administration (U.S FDA) are expected to be a major restraint in growth of the postpartum depression drug market over the forecast period. For instance, in April 2018, the U.S FDA refused New Drug Application of Alkermes plc.’s drug candidate ALKS 5461 which is to be administered orally. The drug could be useful in treating depressive disorders, which cannot be treated by other standard drug therapies. This refusal was due to failures in action of this oral medication.

Postpartum Depression Drug Market– Regional Analysis

On the basis of region, the global postpartum depression drug market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is estimated to hold dominant position in the global postpartum depression drug market during the forecast period, owing to increasing awareness of PPD. For instance, annually, May 2017 is celebrated as a National Maternal Depression Awareness Month recognizing the seriousness of depression during and after pregnancy in the U.S.

Furthermore, Asia Pacific is expected to witness significant growth in the global postpartum depression drug market during the forecast period, owing to increasing prevalence of PDD in the region. For instance, According to World Health Organization (WHO) July 2018 report, 22% of mothers in India suffer from PPD, annually.

Key players operating in the global postpartum depression drug market include, Sage Therapeutics Inc., Sun Pharmaceutical Industries Ltd., Cipla Limited, Intas Pharmaceuticals Ltd., Mylan N.V., Anikem Laboratories, and Shionogi & Co., Ltd.

Postpartum Depression Drug Market– Taxonomy

By Drug Class

• Selective Serotonin Reuptake Inhibitors (SSRIs)
• Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
• Tricyclic Antidepressants
• Atypical Antidepressants
• Monoamine Oxidase Inhibitors (MAOIs)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa